Cita APA

Larkin, J., Del Vecchio, M., Mandalá, M., Gogas, H., Arance Fernandez, A. M., Dalle, S., . . . Weber, J. (2023). Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.

Citación estilo Chicago

Larkin, James, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M. Arance Fernandez, Stéphane Dalle, Luis de la Cruz Merino, y Jeffrey Weber. Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238. 2023.

Cita MLA

Larkin, James, et al. Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238. 2023.